Trials / Terminated
TerminatedNCT03976648
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Orally Administered GLPG1690 in Subjects With Systemic Sclerosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study was to see how GLPG1690 was tolerated in participants with systemic sclerosis and whether there were any side effects in a long-term treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG1690 | film-coated tablets of GLPG1690 to be administered orally |
Timeline
- Start date
- 2019-07-18
- Primary completion
- 2021-04-13
- Completion
- 2021-04-13
- First posted
- 2019-06-06
- Last updated
- 2022-03-29
- Results posted
- 2022-03-15
Locations
14 sites across 5 countries: United States, Belgium, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03976648. Inclusion in this directory is not an endorsement.